How have HUGE shares performed in 2024?

FSD Pharma's stock was trading at $0.9198 at the beginning of 2024. Since then, HUGE stock has decreased by 43.2% and is now trading at $0.5229. View the best growth stocks for 2024 here .

Are investors shorting FSD Pharma?

FSD Pharma saw a decrease in short interest in March. As of March 31st, there was short interest totaling 333,400 shares, a decrease of 23.6% from the March 15th total of 436,600 shares. Based on an average trading volume of 130,700 shares, the short-interest ratio is presently 2.6 days. Approximately 2.1% of the company's stock are sold short. View FSD Pharma's Short Interest .

When is FSD Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our HUGE earnings forecast .

How were FSD Pharma's earnings last quarter?

FSD Pharma Inc. (NASDAQ:HUGE) announced its quarterly earnings data on Tuesday, November, 14th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.14) by $0.11.

What other stocks do shareholders of FSD Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other FSD Pharma investors own include Aurora Cannabis (ACB) , Acasti Pharma (ACST) , Allena Pharmaceuticals (ALNA) , Assertio (ASRT) , Bionano Genomics (BNGO) , Ideanomics (IDEX) , Stealth BioTherapeutics (MITO) , Millendo Therapeutics (MLND) , 9 Meters Biopharma (NMTR) and Selecta Biosciences (SELB) .

How do I buy shares of FSD Pharma?

Shares of HUGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:HUGE

FSD Pharma (HUGE) Stock Price, News & Analysis

→ The #1 Investment of the Decade… (From Porter & Company) (Ad)

Free HUGE Stock Alerts

$0.52

-0.07 (-11.81%)

(As of 04/15/2024 ET)

Compare

Today's Range: $0.51
▼
$0.61
50-Day Range: $0.52
▼
$1.06
52-Week Range: $0.51
▼
$1.90

Volume: 76,735 shs
Average Volume: 126,580 shs
Market Capitalization: $20.58 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get FSD Pharma alerts:

Ad Paradigm Press

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

About FSD Pharma Stock (NASDAQ:HUGE)

FSD Pharma Inc., a biotechnology company, operates in the pharmaceutical research and development business. Its lead candidate is FSD-201, an ultra-micronized palmitoylethanolamide for the treatment of inflammatory diseases. The company is also involved in the research and development of Lucid-Psych, a molecular compound identified for the treatment of mental health disorders; and Lucid-MS, a molecular compound identified for the treatment of neurodegenerative disorders. FSD Pharma Inc. was incorporated in 1998 and is headquartered in Toronto, Canada.

HUGE Stock Price History

30 days | 90 days | 365 days | Advanced Chart

HUGE Stock News Headlines

April 8, 2024 | msn.com

Tesla markets its FSD V12 with impressive real-world results

March 29, 2024 | msn.com

Walgreens’ frail quarter goes beyond the discretionary spending dips afflicting its competitors. It’s ‘just not very good at retailing,’ analyst says

April 16, 2024 | Paradigm Press (Ad)

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

March 28, 2024 | msn.com

Tesla stock slips as analysts issue a fresh round of warnings on Q1 deliveries

March 16, 2024 | benzinga.com

Psychedelics Headlines: Substitution Survey, Frank Herbert's Magic Mushrooms, Celestial Plans And News Review

March 14, 2024 | msn.com

Madrigal and liver drug developers fall ahead of FDA decision on NASH therapy

March 11, 2024 | finance.yahoo.com

FSD Pharma Submits a Phase-1b Clinical Trial Application for Ethics Committee for its Proprietary Beverage unbuzzd(TM)

March 7, 2024 | investing.com

FSD Pharma reports positive Phase-1 MS drug trial results

April 16, 2024 | Paradigm Press (Ad)

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

March 5, 2024 | finance.yahoo.com

FSD Pharma Presents Positive Results on First-In-Human Phase-1 study of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2024 Forum

February 17, 2024 | finance.yahoo.com

HUGE Mar 2024 1.000 call

February 16, 2024 | finanznachrichten.de

FSD Pharma Inc.: FSD Pharma Announces US ATM Offering

February 16, 2024 | finance.yahoo.com

FSD Pharma Announces US ATM Offering

February 6, 2024 | msn.com

Big Pharma Targets Smaller Companies With Megadeals Out of Favor

February 6, 2024 | finanznachrichten.de

FSD Pharma Inc.: Court of Appeal Dismisses Motion for Leave to Appeal Brought by Dr. Raza Bokhari, FSD Pharma Awards Total Approximately $3 Million

February 6, 2024 | finance.yahoo.com

Court of Appeal Dismisses Motion for Leave to Appeal Brought by Dr. Raza Bokhari, FSD Pharma Awards Total Approximately $3 Million

February 3, 2024 | investing.com

FSD Pharma Inc Class B (HUGE)

February 2, 2024 | msn.com

Two women injured in northeast Memphis crash

February 2, 2024 | techcrunch.com

Pitch Deck Teardown: PhageLab’s $11M Series A deck

January 29, 2024 | finanznachrichten.de

FSD Pharma Inc.: FSD Pharma Announces Dr. Sanjiv Chopra is elected to FSD Pharma Board of Directors and Corporate Updates

January 29, 2024 | finance.yahoo.com

FSD Pharma Announces Dr. Sanjiv Chopra is elected to FSD Pharma Board of Directors and Corporate Updates

January 11, 2024 | finance.yahoo.com

GBB Maintains Strong Position in its Ongoing Lawsuit with FSD Pharma After Court Refuses to Dismiss Case

December 22, 2023 | finance.yahoo.com

FSD Pharma Files Final Base Shelf Prospectus to Replace Expired Base Shelf Prospectus and Form F-3 Registration Statement with the SEC

December 5, 2023 | finance.yahoo.com

FSD Pharma Inc. Announces Closing of Private Placement

November 30, 2023 | finance.yahoo.com

FSD Pharma Inc. and Celly Nutrition Corp. Announce Completion of Plan of Arrangement

November 21, 2023 | finance.yahoo.com

FSD Pharma Inc. Securityholders Approve Plan of Arrangement with Celly Nutrition Corp.

November 17, 2023 | finanznachrichten.de

FSD Pharma Inc.: FSD Pharma Announces Distribution Date for Distribution of Celly Shares Pursuant to Plan of Arrangement

See More Headlines

Receive HUGE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for FSD Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/14/2023
Today: 4/15/2024
Next Earnings (Estimated): 5/10/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:HUGE
CUSIP: N/A
CIK: 1771885
Web: fsdpharma.com
Phone: (416) 854-8884
Fax: N/A
Employees: 17
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($0.47)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-17,900,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -112.38%
Return on Assets: -82.46%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.43
Quick Ratio: 2.43

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.33 per share
Price / Book: 1.58

Miscellaneous

Outstanding Shares: 39,360,000
Free Float: 36,002,000
Market Cap: $20.58 million
Optionable: Optionable
Beta: 0.59

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

Mr. Zeeshan Saeed (Age 54)
Founder, CEO, President & Executive Co-Chairman
Comp: $375.98k
Mr. Anthony John Durkacz (Age 48)
Founder & Executive Co-Chairman
Comp: $375.98k
Mr. Nathan Coyle CPA (Age 43)
Chief Financial Officer
Comp: $191.89k
Mr. Donal Carroll CPA (Age 47)
Chief Operating Officer
Comp: $375.98k
Dr. Lakshmi P. Kotra BPHARM (Age 53)
Ph.D., CEO of Lucid & Director
Comp: $331.51k
Dr. Andrzej Chruscinski M.D.
Ph.D., Vice President of Clinical & Scientific Affairs of Lucid
Mr. Kevin Cassidy
Vice President of Quality-Lucid
Ms. Maryann Adesso
Corporate Secretary
Randell Mack
President of FSD BioSciences

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

HUGE Stock Analysis - Frequently Asked Questions

How have HUGE shares performed in 2024?: FSD Pharma's stock was trading at $0.9198 at the beginning of 2024. Since then, HUGE stock has decreased by 43.2% and is now trading at $0.5229.
View the best growth stocks for 2024 here.
Are investors shorting FSD Pharma?: FSD Pharma saw a decrease in short interest in March. As of March 31st, there was short interest totaling 333,400 shares, a decrease of 23.6% from the March 15th total of 436,600 shares. Based on an average trading volume of 130,700 shares, the short-interest ratio is presently 2.6 days. Approximately 2.1% of the company's stock are sold short.
View FSD Pharma's Short Interest.
When is FSD Pharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our HUGE earnings forecast.
How were FSD Pharma's earnings last quarter?: FSD Pharma Inc. (NASDAQ:HUGE) announced its quarterly earnings data on Tuesday, November, 14th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.14) by $0.11.

What other stocks do shareholders of FSD Pharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other FSD Pharma investors own include Aurora Cannabis (ACB), Acasti Pharma (ACST), Allena Pharmaceuticals (ALNA), Assertio (ASRT), Bionano Genomics (BNGO), Ideanomics (IDEX), Stealth BioTherapeutics (MITO), Millendo Therapeutics (MLND), 9 Meters Biopharma (NMTR) and Selecta Biosciences (SELB).
How do I buy shares of FSD Pharma?: Shares of HUGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:HUGE) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

FSD Pharma (HUGE) Stock Price, News & Analysis

About FSD Pharma Stock (NASDAQ:HUGE)

HUGE Stock Price History

HUGE Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

HUGE Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info